CD34 and myeloproliferative neoplasm: IRS2 mRNA expression levels were investigated in primary CD34+ cells from healthy donors and patients with MPN; IRS2 mRNA expression was compared between these groups and among MPN patients stratified according to JAK2 and CALR mutational status.